Advertisement

Canada signs deal with VBI Vaccines to develop coronavirus candidate by 2022

Click to play video: 'Coronavirus: Canada’s top doctor outlines COVID-19 vaccine preparation plan'
Coronavirus: Canada’s top doctor outlines COVID-19 vaccine preparation plan
WATCH: Canada’s top doctor outlines COVID-19 vaccine preparation plan – Sep 18, 2020

VBI Vaccines Inc said on Monday it had entered into an agreement with Canada to develop a potential vaccine for COVID-19 by 2022 through mid-stage trials conducted exclusively in the country.

Canada will contribute around 75% of the U.S.-based company’s development costs and C$55.9 million ($42.2 million) for the project.

VBI Vaccines said last month that together with the National Research Council Canada it was investigating the vaccine candidate, VBI-2900, in preclinical trials.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

As per the agreement, signed last week, the company’s Ottawa-based unit is obligated to complete the vaccine development in or before the first quarter of 2022.

Click to play video: 'Ottawa signs 2 new COVID-19 vaccine deals for Canada'
Ottawa signs 2 new COVID-19 vaccine deals for Canada

There are currently no approved vaccines for COVID-19, but around 38 vaccines are being tested in humans around the world.

Advertisement

Sponsored content

AdChoices